Literature DB >> 16832340

The 26S proteasome system degrades the ERM transcription factor and regulates its transcription-enhancing activity.

J-L Baert1, C Beaudoin, D Monte, C Degerny, S Mauen, Y de Launoit.   

Abstract

ERM is a member of the ETS transcription factor family. High levels of the corresponding mRNA are detected in a variety of human breast cancer cell lines, as well as in aggressive human breast tumors. As ERM protein is almost undetectable in these cells, high degradation of this transcription factor has been postulated. Here we have investigated whether ERM degradation might depend on the proteasome pathway. We show that endogenous and ectopically expressed ERM protein is short-lived protein and undergoes proteasome-dependent degradation. Deletion mutagenesis studies indicate that the 61 C-terminal amino acids of ERM are critical for its proteolysis and serve as a degradation signal. Although ERM conjugates with ubiquitin, this post-translational modification does not depend on the C-terminal domain. We have used an Ets-responsive ICAM-1 reporter plasmid to show that the ubiquitin-proteasome pathway can affect transcriptional function of ERM. Thus, ERM is subject to degradation via the 26S proteasome pathway, and this pathway probably plays an important role in regulating ERM transcriptional activity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16832340     DOI: 10.1038/sj.onc.1209801

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  9 in total

1.  Oncogenic ETS proteins mimic activated RAS/MAPK signaling in prostate cells.

Authors:  Peter C Hollenhorst; Mary W Ferris; Megan A Hull; Heejoon Chae; Sun Kim; Barbara J Graves
Journal:  Genes Dev       Date:  2011-10-15       Impact factor: 11.361

Review 2.  ETV1, 4 and 5: an oncogenic subfamily of ETS transcription factors.

Authors:  Sangphil Oh; Sook Shin; Ralf Janknecht
Journal:  Biochim Biophys Acta       Date:  2012-03-08

3.  ETS variant transcription factor 5 and c-Myc cooperate in derepressing the human telomerase gene promoter via composite ETS/E-box motifs.

Authors:  Fan Zhang; Shuwen Wang; Jiyue Zhu
Journal:  J Biol Chem       Date:  2020-06-09       Impact factor: 5.157

4.  Transcriptome profile of Trypanosoma cruzi-infected cells: simultaneous up- and down-regulation of proliferation inhibitors and promoters.

Authors:  Takako Shigihara; Muneaki Hashimoto; Noriko Shindo; Takashi Aoki
Journal:  Parasitol Res       Date:  2007-12-05       Impact factor: 2.289

5.  Extracellular signal-regulated kinase mitogen-activated protein kinase signaling initiates a dynamic interplay between sumoylation and ubiquitination to regulate the activity of the transcriptional activator PEA3.

Authors:  Baoqiang Guo; Andrew D Sharrocks
Journal:  Mol Cell Biol       Date:  2009-03-23       Impact factor: 4.272

6.  Mutant p53 protects ETS2 from non-canonical COP1/DET1 dependent degradation.

Authors:  Zunamys I Carrero; Madhusudhan Kollareddy; Krishna M Chauhan; Gopalakrishnan Ramakrishnan; Luis A Martinez
Journal:  Oncotarget       Date:  2016-03-15

7.  Activated ALK signals through the ERK-ETV5-RET pathway to drive neuroblastoma oncogenesis.

Authors:  Lucille Lopez-Delisle; Cécile Pierre-Eugène; Caroline Louis-Brennetot; Didier Surdez; Virginie Raynal; Sylvain Baulande; Valentina Boeva; Sandrine Grossetête-Lalami; Valérie Combaret; Michel Peuchmaur; Olivier Delattre; Isabelle Janoueix-Lerosey
Journal:  Oncogene       Date:  2018-01-11       Impact factor: 9.867

Review 8.  Ubiquitin-Mediated Control of ETS Transcription Factors: Roles in Cancer and Development.

Authors:  Charles Ducker; Peter E Shaw
Journal:  Int J Mol Sci       Date:  2021-05-12       Impact factor: 5.923

9.  The Mediator complex subunit MED25 is targeted by the N-terminal transactivation domain of the PEA3 group members.

Authors:  Alexis Verger; Jean-Luc Baert; Kathye Verreman; Frédérique Dewitte; Elisabeth Ferreira; Zoé Lens; Yvan de Launoit; Vincent Villeret; Didier Monté
Journal:  Nucleic Acids Res       Date:  2013-03-26       Impact factor: 16.971

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.